Enveric Biosciences appoints Avani Kanubaddi as President, lowers quorum to one-third

Enveric Biosciences, Inc.

Avani Kanubaddi, current COO since Dec 2020, appointed President effective Nov 15, 2021.
Board approved amendment to bylaws reducing stockholder quorum from majority to one-third.
Kanubaddi previously COO at NEXGEL and founder of Welmedix Healthcare.
Amendment is effective Nov 15, 2021; full text filed as Exhibit 3.1.

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Avani Kanubaddi

President

ENVB · Enveric Biosciences, Inc.

Effective: 2021-11-15
Filed: November 18, 2021, 6:59 PM ET

On November 15, 2021, Enveric Biosciences, Inc. (the “Company”) appointed Avani Kanubaddi, the Chief Operating Officer of the Company, to serve as the Company’s President, effective as of November 15, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Avani Kanubaddi was appointed as President at Enveric Biosciences, Inc..

Action: appointed
Role: President

Exact text from the filing

On November 15, 2021, Enveric Biosciences, Inc. (the “Company”) appointed Avani Kanubaddi, the Chief Operating Officer of the Company, to serve as the Company’s President, effective as of November 15, 2021.

View on SEC.gov

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-21-029223

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.